You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art
|
|---|---|
| Published in |
Vaccine, August 2015
|
| DOI | 10.1016/j.vaccine.2015.07.102 |
| Pubmed ID | |
| Authors |
Zheng Quan Toh, Paul V. Licciardi, James Fong, Suzanne M. Garland, Sepehr N. Tabrizi, Fiona M. Russell, Edward K. Mulholland |
| Abstract |
Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil(®) and Cervarix(®) vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vagina cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil(®) vaccine also offer additional protection against anal cancer precursors. However, high costs of HPV vaccines and the logistics of delivering a three-dose schedule over 6 months are challenging in countries with limited resources. Several studies have demonstrated non-inferiority in antibody response between adolescents (9-15 years old) who received two doses (6 months apart) and women (>15 years old) who received the standard three-dose schedule. These studies provided evidence for the World Health Organization and European Medical Association to revise its recommendation to give two instead of three doses of HPV vaccine to adolescents below 15 years of age, provided the 2nd dose is given 6 months apart. Although reduced dose schedules can alleviate costs and logistics associated with HPV vaccination, especially in resource-poor countries, there are still gaps in this area of research, particularly regarding long-term protection. This review discusses the findings on antibody response and clinical outcomes in studies evaluating reduced dose HPV schedules, and highlights the important considerations of its implementation. In addition, other important immunological biomarkers that may be associated with long-term protection are highlighted and discussed. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 33% |
| United States | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Ecuador | 1 | <1% |
| Unknown | 107 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 19 | 17% |
| Student > Bachelor | 14 | 13% |
| Researcher | 14 | 13% |
| Student > Ph. D. Student | 10 | 9% |
| Student > Doctoral Student | 8 | 7% |
| Other | 20 | 18% |
| Unknown | 24 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 26% |
| Biochemistry, Genetics and Molecular Biology | 13 | 12% |
| Immunology and Microbiology | 9 | 8% |
| Agricultural and Biological Sciences | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 6% |
| Other | 16 | 15% |
| Unknown | 31 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2015.
All research outputs
#8,474,477
of 25,374,647 outputs
Outputs from Vaccine
#8,374
of 16,509 outputs
Outputs of similar age
#93,473
of 275,212 outputs
Outputs of similar age from Vaccine
#92
of 199 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 16,509 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.7. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,212 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 199 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.